Research ResourceCancer therapy

Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer

See allHide authors and affiliations

Science Signaling  22 Jan 2019:
Vol. 12, Issue 565, eaau2875
DOI: 10.1126/scisignal.aau2875

Blocking drug resistance

The identification of “cancer drivers” enables the development of targeted therapeutics, but tumors often exhibit—or inevitably develop—resistance to these drugs. Knowing how tumors do this is essential for better and more durable clinical outcomes in patients. Using a multiomics approach, Schwill et al. studied the activities of kinase networks in HER2-positive breast cancer cells in response to HER2-targeted drugs. From these networks, they identified critical proteins, such as the kinase FAK1, that enabled sustained cell survival. Combining an FAK1 inhibitor with a HER2-blocking agent synergistically induced cell death. These findings may inform the development of more effective combination therapies for patients with HER2-positive breast cancer.

View Full Text

Stay Connected to Science Signaling